Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus

NARecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

May 30, 2025

Conditions
Chronic Kidney DiseasesType2Diabetes
Interventions
OTHER

Alert-based computerized decision support

For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Brigham and Women's Hospital

OTHER